Allogeneic Stem Cell Therapy Market Los Angeles, United State- The global Allogeneic Stem Cell Therapy market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Allogeneic Stem Cell Therapy market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Allogeneic Stem Cell Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Allogeneic Stem Cell Therapy market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Allogeneic Stem Cell Therapy market.
Leading players of the global Allogeneic Stem Cell Therapy market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Allogeneic Stem Cell Therapy market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Allogeneic Stem Cell Therapy market. It also provides useful recommendations for new as well as established players of the global Allogeneic Stem Cell Therapy market.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/2043756/global-and-china-allogeneic-stem-cell-therapy-market
Allogeneic Stem Cell Therapy Market Leading Players
, Escape Therapeutics, Inc., Lonza Group Ltd., Osiris Therapeutics (Smith & Nephew), NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Anterogen, MolMed S.p.A., Takeda (TiGenix)
Allogeneic Stem Cell Therapy Segmentation by Product
, Adult Stem Cell Therapy, Human Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Others Allogeneic Stem Cell Therapy
Allogeneic Stem Cell Therapy Segmentation by Application
Musculoskeletal Disorder, Wounds & Injuries, Cardiovascular Diseases, Others
Report Objectives
Analyzing the size of the global Allogeneic Stem Cell Therapy market on the basis of value and volume.
Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Allogeneic Stem Cell Therapy market.
Exploring the key dynamics of the global Allogeneic Stem Cell Therapy market.
Highlighting important trends of the global Allogeneic Stem Cell Therapy market in terms of production, revenue, and sales.
Deeply profiling top players of the global Allogeneic Stem Cell Therapy market and showing how they compete in the industry.
Studying manufacturing processes and costs, product pricing, and various trends related to them.
Showing the performance of different regions and countries in the global Allogeneic Stem Cell Therapy market.
Forecasting the market size and share of all segments, regions, and the global market.
Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/2043756/global-and-china-allogeneic-stem-cell-therapy-market
Table of Contents.
1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Allogeneic Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.2.2 Adult Stem Cell Therapy1.2.3 Human Embryonic Stem Cell Therapy1.2.4 Induced Pluripotent Stem Cell Therapy1.2.5 Others1.3 Market by Application1.3.1 Global Allogeneic Stem Cell Therapy Market Share by Application: 2020 VS 20261.3.2 Musculoskeletal Disorder1.3.3 Wounds & Injuries1.3.4 Cardiovascular Diseases1.3.5 Others1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Allogeneic Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Allogeneic Stem Cell Therapy Growth Trends by Regions2.2.1 Allogeneic Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Allogeneic Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Allogeneic Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Allogeneic Stem Cell Therapy Players by Market Size3.1.1 Global Top Allogeneic Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Allogeneic Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.2 Global Allogeneic Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Allogeneic Stem Cell Therapy Revenue3.4 Global Allogeneic Stem Cell Therapy Market Concentration Ratio3.4.1 Global Allogeneic Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Allogeneic Stem Cell Therapy Revenue in 20193.5 Key Players Allogeneic Stem Cell Therapy Area Served3.6 Key Players Allogeneic Stem Cell Therapy Product Solution and Service3.7 Date of Enter into Allogeneic Stem Cell Therapy Market3.8 Mergers & Acquisitions, Expansion Plans 4 Allogeneic Stem Cell Therapy Breakdown Data by Type (2015-2026)4.1 Global Allogeneic Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Allogeneic Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Allogeneic Stem Cell Therapy Breakdown Data by Application (2015-2026)5.1 Global Allogeneic Stem Cell Therapy Historic Market Size by Application (2015-2020)5.2 Global Allogeneic Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Allogeneic Stem Cell Therapy Market Size (2015-2026)6.2 North America Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)6.3 North America Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)6.4 North America Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Allogeneic Stem Cell Therapy Market Size (2015-2026)7.2 Europe Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)7.3 Europe Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)7.4 Europe Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Allogeneic Stem Cell Therapy Market Size (2015-2026)8.2 China Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)8.3 China Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)8.4 China Allogeneic Stem Cell Therapy Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Allogeneic Stem Cell Therapy Market Size (2015-2026)9.2 Japan Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)9.3 Japan Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)9.4 Japan Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 South Korea10.1 South Korea Allogeneic Stem Cell Therapy Market Size (2015-2026)10.2 South Korea Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)10.3 South Korea Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)10.4 South Korea Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Escape Therapeutics, Inc.11.1.1 Escape Therapeutics, Inc. Company Details11.1.2 Escape Therapeutics, Inc. Business Overview11.1.3 Escape Therapeutics, Inc. Allogeneic Stem Cell Therapy Introduction11.1.4 Escape Therapeutics, Inc. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020))11.1.5 Escape Therapeutics, Inc. Recent Development11.2 Lonza Group Ltd.11.2.1 Lonza Group Ltd. Company Details11.2.2 Lonza Group Ltd. Business Overview11.2.3 Lonza Group Ltd. Allogeneic Stem Cell Therapy Introduction11.2.4 Lonza Group Ltd. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.2.5 Lonza Group Ltd. Recent Development11.3 Osiris Therapeutics (Smith & Nephew)11.3.1 Osiris Therapeutics (Smith & Nephew) Company Details11.3.2 Osiris Therapeutics (Smith & Nephew) Business Overview11.3.3 Osiris Therapeutics (Smith & Nephew) Allogeneic Stem Cell Therapy Introduction11.3.4 Osiris Therapeutics (Smith & Nephew) Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.3.5 Osiris Therapeutics (Smith & Nephew) Recent Development11.4 NuVasive11.4.1 NuVasive Company Details11.4.2 NuVasive Business Overview11.4.3 NuVasive Allogeneic Stem Cell Therapy Introduction11.4.4 NuVasive Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.4.5 NuVasive Recent Development11.5 Chiesi Pharmaceuticals11.5.1 Chiesi Pharmaceuticals Company Details11.5.2 Chiesi Pharmaceuticals Business Overview11.5.3 Chiesi Pharmaceuticals Allogeneic Stem Cell Therapy Introduction11.5.4 Chiesi Pharmaceuticals Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.5.5 Chiesi Pharmaceuticals Recent Development11.6 JCR Pharmaceutical11.6.1 JCR Pharmaceutical Company Details11.6.2 JCR Pharmaceutical Business Overview11.6.3 JCR Pharmaceutical Allogeneic Stem Cell Therapy Introduction11.6.4 JCR Pharmaceutical Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.6.5 JCR Pharmaceutical Recent Development11.7 Pharmicell11.7.1 Pharmicell Company Details11.7.2 Pharmicell Business Overview11.7.3 Pharmicell Allogeneic Stem Cell Therapy Introduction11.7.4 Pharmicell Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.7.5 Pharmicell Recent Development11.8 Anterogen11.8.1 Anterogen Company Details11.8.2 Anterogen Business Overview11.8.3 Anterogen Allogeneic Stem Cell Therapy Introduction11.8.4 Anterogen Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.8.5 Anterogen Recent Development11.9 MolMed S.p.A.11.9.1 MolMed S.p.A. Company Details11.9.2 MolMed S.p.A. Business Overview11.9.3 MolMed S.p.A. Allogeneic Stem Cell Therapy Introduction11.9.4 MolMed S.p.A. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.9.5 MolMed S.p.A. Recent Development11.10 Takeda (TiGenix)11.10.1 Takeda (TiGenix) Company Details11.10.2 Takeda (TiGenix) Business Overview11.10.3 Takeda (TiGenix) Allogeneic Stem Cell Therapy Introduction11.10.4 Takeda (TiGenix) Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.10.5 Takeda (TiGenix) Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.
Continue reading here:
Allogeneic Stem Cell Therapy Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges|Escape...
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]